Literature DB >> 29163959

The gut microbiota: A new potential driving force in liver cirrhosis and hepatocellular carcinoma.

Marco Sanduzzi Zamparelli1, Alba Rocco1, Debora Compare1, Gerardo Nardone1.   

Abstract

The gut microbiota has recently been recognized as a major environmental factor in the pathophysiology of many human diseases. The anatomical and function connection existing between gut and liver provides the theoretical basis to assume the liver is a major target for gut microbes. In the last decades, numerous studies reported an altered composition of gut microbiota in patients with liver cirrhosis and a progressively marked dysbiosis with worsening of the liver disease. The risk of developing hepatocellular carcinoma, the deadliest complication of liver cirrhosis, is widely variable among cirrhotic patients, thus suggesting a complexity of genetic and environmental factors implicated in hepatocarcinogenesis. Gut microbiota is now emerging as a plausible candidate to explain this variability. In this manuscript we review the human and the experimental evidence supporting the potential implication of gut microbiota in the promotion, progression and complication of liver disease.

Entities:  

Keywords:  Gut bacteria; bacterial translocation; dysbiosis; liver carcinogenesis

Year:  2017        PMID: 29163959      PMCID: PMC5676553          DOI: 10.1177/2050640617705576

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN: 2050-6406            Impact factor:   4.623


  58 in total

Review 1.  Pathological bacterial translocation in liver cirrhosis.

Authors:  Reiner Wiest; Melissa Lawson; Markus Geuking
Journal:  J Hepatol       Date:  2013-08-28       Impact factor: 25.083

2.  Characterization of fecal microbial communities in patients with liver cirrhosis.

Authors:  Yanfei Chen; Fengling Yang; Haifeng Lu; Baohong Wang; Yunbo Chen; Dajiang Lei; Yuezhu Wang; Baoli Zhu; Lanjuan Li
Journal:  Hepatology       Date:  2011-06-26       Impact factor: 17.425

3.  Comparison of the gut microbe profiles and numbers between patients with liver cirrhosis and healthy individuals.

Authors:  Jianjun Liu; Dachang Wu; Ayaz Ahmed; Xinli Li; Yufang Ma; Li Tang; Dianjun Mo; Yue Ma; Yi Xin
Journal:  Curr Microbiol       Date:  2012-04-07       Impact factor: 2.188

Review 4.  Gut microbiome and liver diseases.

Authors:  Herbert Tilg; Patrice D Cani; Emeran A Mayer
Journal:  Gut       Date:  2016-10-08       Impact factor: 23.059

5.  Large-scale survey of gut microbiota associated with MHE Via 16S rRNA-based pyrosequencing.

Authors:  Zhigang Zhang; Huiqin Zhai; Jiawei Geng; Rui Yu; Haiqing Ren; Hong Fan; Peng Shi
Journal:  Am J Gastroenterol       Date:  2013-07-23       Impact factor: 10.864

6.  Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia.

Authors:  Tilman M Bauer; Henning Schwacha; Bernhard Steinbrückner; Folke E Brinkmann; Anette K Ditzen; John J Aponte; Klaus Pelz; Dieter Berger; Manfred Kist; Hubert E Blum
Journal:  Am J Gastroenterol       Date:  2002-09       Impact factor: 10.864

Review 7.  The enteric microbiome in hepatobiliary health and disease.

Authors:  James H Tabibian; Cyril Varghese; Nicholas F LaRusso; Steven P O'Hara
Journal:  Liver Int       Date:  2015-12-12       Impact factor: 5.828

8.  Abnormal fecal microbiota community and functions in patients with hepatitis B liver cirrhosis as revealed by a metagenomic approach.

Authors:  Xiao Wei; Xiabei Yan; Dayang Zou; Zhan Yang; Xuesong Wang; Wei Liu; Simiao Wang; Xuelian Li; Juqiang Han; Liuyu Huang; Jing Yuan
Journal:  BMC Gastroenterol       Date:  2013-12-26       Impact factor: 3.067

9.  Deep sequencing reveals microbiota dysbiosis of tongue coat in patients with liver carcinoma.

Authors:  Haifeng Lu; Zhigang Ren; Ang Li; Hua Zhang; Jianwen Jiang; Shaoyan Xu; Qixia Luo; Kai Zhou; Xiaoli Sun; Shusen Zheng; Lanjuan Li
Journal:  Sci Rep       Date:  2016-09-08       Impact factor: 4.379

10.  Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology.

Authors:  Yanfei Chen; Feng Ji; Jing Guo; Ding Shi; Daiqiong Fang; Lanjuan Li
Journal:  Sci Rep       Date:  2016-09-30       Impact factor: 4.379

View more
  20 in total

1.  Improve gut microbiome: a new horizon of cancer therapy.

Authors:  Hiroshi Fukui
Journal:  Hepatobiliary Surg Nutr       Date:  2017-12       Impact factor: 7.293

2.  Dietary Additives and Supplements Revisited: The Fewer, the Safer for Liver and Gut Health.

Authors:  Rachel Golonka; Beng San Yeoh; Matam Vijay-Kumar
Journal:  Curr Pharmacol Rep       Date:  2019-06-10

3.  Association of Intake of Whole Grains and Dietary Fiber With Risk of Hepatocellular Carcinoma in US Adults.

Authors:  Wanshui Yang; Yanan Ma; Yue Liu; Stephanie A Smith-Warner; Tracey G Simon; Dawn Q Chong; Qibin Qi; Jeffrey A Meyerhardt; Edward L Giovannucci; Andrew T Chan; Xuehong Zhang
Journal:  JAMA Oncol       Date:  2019-06-01       Impact factor: 31.777

4.  The selective PPAR-delta agonist seladelpar reduces ethanol-induced liver disease by restoring gut barrier function and bile acid homeostasis in mice.

Authors:  Huikuan Chu; Lu Jiang; Bei Gao; Nagsen Gautam; Jawaher A Alamoudi; Sonja Lang; Yanhan Wang; Yi Duan; Yazen Alnouti; Edward E Cable; Bernd Schnabl
Journal:  Transl Res       Date:  2020-06-15       Impact factor: 7.012

Review 5.  The Bacterial Microbiota of Gastrointestinal Cancers: Role in Cancer Pathogenesis and Therapeutic Perspectives.

Authors:  Lina Elsalem; Ahmad A Jum'ah; Mahmoud A Alfaqih; Osama Aloudat
Journal:  Clin Exp Gastroenterol       Date:  2020-05-06

6.  The effect of fecal microbiota transplantation on Hepatic myelopathy: A case report.

Authors:  Lin Sun; Jun Li; Li-Li Lan; Xiao-An Li
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

7.  Effects of knockout of lincRNA-p21 on the proliferation, migration and invasion ability of HepG2 liver cancer cells.

Authors:  Tongshan Wang; Jun Liu; Suihui Li; Zhengang Yuan; Xiangzhong Huang
Journal:  Oncol Lett       Date:  2019-04-01       Impact factor: 2.967

Review 8.  Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts.

Authors:  Ralf Weiskirchen; Sabine Weiskirchen; Frank Tacke
Journal:  F1000Res       Date:  2018-06-27

Review 9.  Gut⁻Liver Axis: How Do Gut Bacteria Influence the Liver?

Authors:  Peter Christopher Konturek; Igor Alexander Harsch; Kathrin Konturek; Monic Schink; Thomas Konturek; Markus F Neurath; Yurdaguel Zopf
Journal:  Med Sci (Basel)       Date:  2018-09-17

10.  Clinical impact of microbiome in patients with decompensated cirrhosis.

Authors:  Theodora Oikonomou; George V Papatheodoridis; Michael Samarkos; Ioannis Goulis; Evangelos Cholongitas
Journal:  World J Gastroenterol       Date:  2018-09-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.